COGT Profile
Cogent Biosciences, Inc. is a biotechnology company dedicated to developing precision therapies for genetically defined diseases, with a focus on targeted treatment strategies. The company's lead product candidate, CGT9486, is a selective tyrosine kinase inhibitor designed to address the KIT D816V mutation, which is a key driver of systemic mastocytosis. Additionally, CGT9486 targets other mutations in KIT exon 17, which are prevalent in advanced gastrointestinal stromal tumors.
Cogent Biosciences is advancing its pipeline through strategic partnerships and licensing agreements. Notably, the company has a licensing agreement with Plexxikon Inc. to research, develop, and commercialize bezuclastinib, a promising compound in its therapeutic arsenal. This collaboration highlights Cogent's commitment to leveraging innovative science and external expertise to accelerate the development of its therapies.
In addition to its primary focus on KIT mutations, Cogent Biosciences explores other avenues for precision medicine, with an emphasis on identifying and targeting specific genetic alterations that drive disease. The company's approach integrates advanced drug discovery techniques and a deep understanding of genetic pathways to develop targeted treatments that offer new hope for patients with previously unmet medical needs.
Founded in 2014 and headquartered in Cambridge, Massachusetts, Cogent Biosciences was formerly known as Unum Therapeutics Inc. The company rebranded in October 2020 to reflect its evolving focus on precision medicine and its commitment to advancing targeted therapies for complex genetic disorders.
|
